obeticholic acid Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5155 459789-99-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • obeticholic acid
  • ocaliva
  • 6-ECDCA
  • 6ECDCA
  • INT-747
obeticholic acid is an agonist for FXR, a nuclear receptor expressed in the liver and intestine
  • Molecular weight: 420.63
  • Formula: C26H44O4
  • CLOGP: 5.36
  • LIPINSKI: 1
  • HAC: 4
  • HDO: 3
  • TPSA: 77.76
  • ALOGS: -4.58
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
10 mg O

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 12, 2016 EMA Intercept Pharma Ltd
May 27, 2016 FDA INTERCEPT PHARMACEUTICALS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 1545.09 31.59 598 2989 241754 46440721
Therapy cessation 253.69 31.59 90 3497 26539 46655936
Therapy interrupted 160.26 31.59 51 3536 10740 46671735
Product dose omission issue 150.58 31.59 115 3472 168405 46514070
Hospitalisation 141.18 31.59 77 3510 63308 46619167
Fatigue 95.70 31.59 168 3419 608529 46073946
Blood alkaline phosphatase abnormal 78.97 31.59 15 3572 358 46682117
Insurance issue 65.18 31.59 17 3570 1761 46680714
Constipation 58.01 31.59 69 3518 174028 46508447
Emergency care 50.76 31.59 12 3575 830 46681645
Dry skin 47.78 31.59 33 3554 40983 46641492
Blood alkaline phosphatase increased 44.11 31.59 31 3556 39578 46642897
Therapy change 40.12 31.59 15 3572 5075 46677400
Varices oesophageal 32.44 31.59 11 3576 2808 46679667
Rehabilitation therapy 32.39 31.59 9 3578 1183 46681292
Hepatic cirrhosis 31.86 31.59 18 3569 15714 46666761

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 177.99 46.36 53 148 118151 29834126

Pharmacologic Action:

SourceCodeDescription
ATC A05AA04 ALIMENTARY TRACT AND METABOLISM
BILE AND LIVER THERAPY
BILE THERAPY
Bile acids and derivatives
FDA MoA N0000192560 Farnesoid X Receptor Agonists
FDA EPC N0000192561 Farnesoid X Receptor Agonist
CHEBI has role CHEBI:62868 antihepatotoxic agent
CHEBI has role CHEBI:132972 bar agonist

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Primary cholangitis indication 17266006

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.92 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2021 NEW CHEMICAL ENTITY
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2021 NEW CHEMICAL ENTITY
10MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2023 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINULLTION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INULLDEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNULLBLE TO TOLERATE UDCA
5MG OCALIVA INTERCEPT PHARMS INC N207999 May 27, 2016 RX TABLET ORAL May 27, 2023 TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC) IN COMBINULLTION WITH URSODEOXYCHOLIC ACID (UDCA) IN ADULTS WITH AN INULLDEQUATE RESPONSE TO UDCA, OR AS MONOTHERAPY IN ADULTS UNULLBLE TO TOLERATE UDCA

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bile acid receptor Nuclear hormone receptor AGONIST EC50 7.00 SCIENTIFIC LITERATURE DRUG LABEL
G-protein coupled bile acid receptor 1 GPCR EC50 7 CHEMBL

External reference:

IDSource
4035786 VANDF
C1143018 UMLSCUI
CHEBI:43602 CHEBI
CHC PDB_CHEM_ID
IU6 PDB_CHEM_ID
D09360 KEGG_DRUG
447715 PUBCHEM_CID
CHEMBL566315 ChEMBL_ID
DB05990 DRUGBANK_ID
C464660 MESH_SUPPLEMENTAL_RECORD_UI
3435 IUPHAR_LIGAND_ID
9084 INN_ID
0462Z4S4OZ UNII
1798288 RXNORM
241391 MMSL
31698 MMSL
d08442 MMSL
016875 NDDF
720257002 SNOMEDCT_US
763557003 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-005 TABLET, FILM COATED 5 mg ORAL NDA 32 sections
Ocaliva HUMAN PRESCRIPTION DRUG LABEL 1 69516-010 TABLET, FILM COATED 10 mg ORAL NDA 32 sections